Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
immuno-oncology
Fierce Pharma
Editor's Corner—Summit must submit to Big Pharma, stat
The debatable HARMONi data, along with the trial design flaws and a rapidly evolving competitive landscape, suggest a need for Summit to partner up.
Angus Liu
Sep 10, 2025 2:50pm
Bicycle lays off staff as Genentech rides away from R&D pact
Aug 8, 2025 8:50am
Leads Biolabs hits Hong Kong stock exchange in $189M IPO
Jul 25, 2025 10:59am
Pfizer CEO makes case for $6B bet on 'fabulous' bispecific
Jun 10, 2025 9:56am
To Gilead's new CMO, pipeline diversification is key
Jun 9, 2025 10:00am
BMS inks $11B biobucks BioNTech deal to join bispecific rush
Jun 2, 2025 8:59am